

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai MicroPort MedBot (Group) Co., Ltd.**  
**上海微创医疗机器人（集团）股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2252)**

**VOLUNTARY ANNOUNCEMENT**  
**BUSINESS UPDATE**

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company updates on the latest business development of the Group.

According to preliminary internal statistics, during the 12 months ended 31 December 2024 (the “**Reporting Period**”), the cumulative order volume of the Group's laparoscopic, orthopedic and vascular interventional core products has exceeded 100 units.

**Toumai Laparoscopic Surgical Robot**

During the Reporting Period, global orders of Toumai Laparoscopic Surgical Robot (“**Toumai**”) reached 39 units, with commercial installations breaking through 30 units, and nearly 60 cumulative commercial orders globally. Toumai's market share in the domestic market in China continues to rise, with the proportion of provincial top tertiary hospitals and national top 100 hospitals increasing to over 60%. In the international market, within just one year, Toumai not only expanded into emerging markets in Asia, Africa, and Latin America but also achieved breakthroughs in high-end markets in Europe and America, securing over 20 commercial orders. More than 10 hospitals have seen Toumai's surgical volume exceed 100 cases. Among them, Shanghai Pulmonary Hospital\* has conducted nearly 500 commercial clinical surgeries in 10 months since February 2024. Hebei Medical University Fourth Hospital\*, Xinjiang Autonomous Region People's Hospital\*, Gansu Provincial People's Hospital\*, and Jingzhou First People's Hospital\* have all accumulated surgical volumes close to 300 cases.

So far, Toumai's cumulative remote surgical volume is close to 300 cases, with a 100% implementation success rate, setting 25 world records. Among them, a Moroccan surgical expert used Toumai to successfully perform a remote prostate cancer radical surgery for a patient in Casablanca, Morocco, 12,000 kilometers away in Shanghai, China. The entire surgery was completed remotely with a one-way delay of only about 100 milliseconds. This surgery, spanning Asia and Africa with a two-way communication distance exceeding 30,000 kilometers, set a new world record for the longest-distance remote human surgery to date. Toumai also completed the world's first ultra-long-distance pancreaticoduodenectomy, becoming the only laparoscopic surgical robot in the world to date that has achieved full coverage of remote surgery and high-difficulty complex routine surgery in multiple departments. Additionally, Toumai successfully implemented the world's first robot satellite remote surgery, completing two consecutive liver cancer tumor resection satellite remote surgeries.

In May 2024, Toumai obtained the EU CE certification (MDR) for use in urological, general, thoracic, and gynecological laparoscopic surgeries. In August, Toumai received the ANVISA certification in Brazil. These certifications from multiple international authoritative regulatory agencies indicate the stability, clinical efficacy, safety, innovation level, and technical content of Toumai robots. Currently, Toumai has submitted marketing certification applications in more than 20 countries or regions and is expected to receive intensive approvals in 2025.

### **SkyWalker Orthopedic Surgical Robot**

During the Reporting Period, global orders of SkyWalker Orthopedic Surgical Robot (“**SkyWalker**”) reached 25 units, with cumulative orders exceeding 40 units, covering medical institutions in five continents, including China, the United States, Germany, Italy, Belgium, Greece, Australia, and Brazil. As at the Reporting Period, SkyWalker has completed nearly 200 TKA surgeries at Gansu Provincial People's Hospital\* and over 200 TKA surgeries at Nettetel City Hospital in Germany.

### **R-ONE Vascular Interventional Surgical Robot**

R-ONE Vascular Interventional Surgical Robot is currently the only coronary interventional surgical robot product that has been marketed and sold in domestic China. In December 2024, it successfully won purchase order bids from five top public hospitals in Shanghai, including Fudan University Affiliated Zhongshan Hospital\*, with domestic orders reaching eight units and global orders of 18 units.

**The board of directors of the Company wishes to remind shareholders and potential investors of the securities of the Company that the above information is unaudited and is based on preliminary internal information of the Group, which may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by**

**the Company on an annual or half-yearly basis due to various uncertainties during the process of collating such sales information.**

**Shareholders and potential investors of the Company are cautioned not to unduly rely on such information and are advised to exercise caution in dealing in the Company's securities.**

By order of the Board  
**Shanghai MicroPort MedBot (Group) Co., Ltd.**  
**Mr. Sun Hongbin**  
*Chairman*

Shanghai, China, 24 January 2025

*As at the date of this announcement, the executive Directors are Dr. He Chao and Ms. Fang Cong, the non-executive Directors are Mr. Sun Hongbin, Mr. Chen Xinxing and Mr. Chen Chen, and the independent non-executive Directors are Dr. Li Minghua, Mr. Yao Haisong and Mr. Chung Wai Man.*

*\* for identification purposes only*